Perinuclear positioning of endosomes can affect PS-ASO activities
Liang, X.H., Nichols, J.G., Tejera, D., Crooke, S.T.
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
Anderson, B.A., Freestone, G.C., Low, A., De-Hoyos, C.L., Iii, W.J.D., Østergaard, M.E., Migawa, M.T., Fazio, M., Wan, W.B., Berdeja, A., Scandalis, E., Burel, S.A., Vickers, T.A., Crooke, S.T., Swayze, E.E., Liang, X., Seth, P.P.
Towards Next Generation Antisense Oligonucleotides: Mesylphosphoramidate Modification Improves Therapeutic Index and Duration of Effect of Gapmer ASO
Anderson, B.A., Freestone, G.C., Low, A., De-Hoyos, C.L., Iii, W.J.D., Østergaard, M.E., Migawa, M.T., Fazio, M., Wan, W.B., Berdeja, A., Scandalis, E., Burel, S.A., Vickers, T.A., Crooke, S.T., Swayze, E.E., Liang, X., Seth, P.P.
Site-specific incorporation of 5′-methyl DNA enhances the therapeutic profile of gapmer ASOs
Vasquez, G., Freestone, G.C., Wan, W.B., Low, A., De Hoyos, C.L., Yu, J., Prakash, T.P., Østergaard, M.E., Liang, X.H., Crooke, S.T., Swayze, E.E., Migawa, M.T., Seth, P.P.
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S.T., Vickers, T.A., Liang, X.H.
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
Migawa, M.T., Shen, W, Wan, W.B., Vasquez, G., Oestergaard, M.E., Low, A., De Hoyos, C.L., Gupta, R., Murray, S., Tanowitz, M., Bell, M., Nichols, J.G., Gaus, H., Liang, X.H., Swayze, E.E., Crooke, S.T., Seth, P.P.
